Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
Grigoris T Gerotziafas,Mariella Catalano,Mary-Paula Colgan,Zsolt Pecsvarady,Jean Claude Wautrecht,Bahare Fazeli,Dan-Mircea Olinic,Katalin Farkas,Ismail Elalamy,Anna Falanga,Jawed Fareed,Chryssa Papageorgiou,Rosella S Arellano,Petros Agathagelou,Darco Antic,Luciana Auad,Ljiljana Banfic,John R Bartolomew,Bela Benczur,Melissa B Bernardo,Francesco Boccardo,Renate Cifkova,Benilde Cosmi,Sergio De Marchi,Evangelos Dimakakos,Meletios A Dimopoulos,Gabriel Dimitrov,Isabelle Durand-Zaleski,Michael Edmonds,Essam Abo El Nazar,Dilek Erer,Omar L Esponda,Paolo Gresele,Michael Gschwandtner,Yongquan Gu,Mónica Heinzmann,Naomi M Hamburg,Amer Hamadé,Noor-Ahmed Jatoi,Oguz Karahan,Debora Karetova,Thomas Karplus,Peter Klein-Weigel,Endre Kolossvary,Matija Kozak,Eleftheria Lefkou,Gianfranco Lessiani,Aaron Liew,Antonella Marcoccia,Peter Marshang,George Marakomichelakis,Jiri Matuska,Luc Moraglia,Sergio Pillon,Pavel Poredos,Manlio Prior,David Raymund K Salvador,Oliver Schlager,Gerit Schernthaner,Alexander Sieron,Jonas Spaak,Alex Spyropoulos,Muriel Sprynger,Dusan Suput,Agata Stanek,Viera Stvrtinova,Andrzej Szuba,Alfonso Tafur,Patrick Vandreden,Panagiotis E Vardas,Dragan Vasic,Miikka Vikkula,Paul Wennberg,Zhenguo Zhai,Scientific Reviewer Committee,Behnood Bikdeli,Yutao Guo,Job Harenberg,Yu Hu,Gregory Y H Lip,Vanessa Roldan
DOI: https://doi.org/10.1055/s-0040-1715798
Abstract:COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.